Literature DB >> 19534597

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.

Ellen Murphy1, Lubomira Andrew, Kwok-Leung Lee, Deborah A Dilts, Lorna Nunez, Pamela S Fink, Karita Ambrose, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Paula Kriz, Martin Musilek, Jitka Kalmusova, Dominique A Caugant, Torill Alvestad, Leonard W Mayer, Claudio T Sacchi, Xin Wang, Diana Martin, Anne von Gottberg, Mignon du Plessis, Keith P Klugman, Annaliesa S Anderson, Kathrin U Jansen, Gary W Zlotnick, Susan K Hoiseth.   

Abstract

BACKGROUND: Recombinant forms of Neisseria meningitidis human factor H binding protein (fHBP) are undergoing clinical trials in candidate vaccines against invasive meningococcal serogroup B disease. We report an extensive survey and phylogenetic analysis of the diversity of fhbp genes and predicted protein sequences in invasive clinical isolates obtained in the period 2000-2006.
METHODS: Nucleotide sequences of fhbp genes were obtained from 1837 invasive N. meningitidis serogroup B (MnB) strains from the United States, Europe, New Zealand, and South Africa. Multilocus sequence typing (MLST) analysis was performed on a subset of the strains.
RESULTS: Every strain contained the fhbp gene. All sequences fell into 1 of 2 subfamilies (A or B), with 60%-75% amino acid identity between subfamilies and at least 83% identity within each subfamily. One fHBP sequence may have arisen via inter-subfamily recombination. Subfamily B sequences were found in 70% of the isolates, and subfamily A sequences were found in 30%. Multiple fHBP variants were detected in each of the common MLST clonal complexes. All major MLST complexes include strains in both subfamily A and subfamily B.
CONCLUSIONS: The diversity of strains observed underscores the importance of studying the distribution of the vaccine antigen itself rather than relying on common epidemiological surrogates such as MLST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19534597     DOI: 10.1086/600141

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  78 in total

1.  Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Authors:  Kathleen Y Dunphy; Peter T Beernink; Barbara Brogioni; Dan M Granoff
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

2.  A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Authors:  Monica Konar; Rolando Pajon; Peter T Beernink
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

3.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

4.  Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008.

Authors:  Mignon du Plessis; Chivonne Moodley; Kedibone M Mothibeli; Azola Fali; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

5.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

6.  Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.

Authors:  Susanna Esposito; Alberto Zampiero; Leonardo Terranova; Valentina Montinaro; Alessia Scala; Valentina Ansuini; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

7.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

8.  Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Authors:  Serena Giuntini; Rolando Pajon; Sanjay Ram; Dan M Granoff
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

9.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

Review 10.  The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Authors:  Gary W Zlotnick; Thomas R Jones; Paul Liberator; Li Hao; Shannon Harris; Lisa K McNeil; Duzhang Zhu; John Perez; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.